Zacks7d agobullish
Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance RaisedBiogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
536last 24h
2517last 7d
483● bullish (7d)
258● bearish (7d)
197publishers